ResearcherWestern UniversityActive in the last 2 years

Evelyn V. Waugh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1720-7281; OpenAlex author ID A5085096216. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2024: 1 paper

Papers 1

Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer. Co-author DOI 10.14701/ahbps.23-107 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Daniel Adam Breadner · 1 shared paper, 2024 · strength 0.22
- Paper Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer. DOI 10.14701/ahbps.23-107 ↗
Ephraim Shin-Tian Tang · 1 shared paper, 2024 · strength 0.22
- Paper Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer. DOI 10.14701/ahbps.23-107 ↗
Anton I. Skaro · 1 shared paper, 2024 · strength 0.22
- Paper Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer. DOI 10.14701/ahbps.23-107 ↗
Juan Glinka · 1 shared paper, 2024 · strength 0.22
- Paper Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer. DOI 10.14701/ahbps.23-107 ↗
Ken A. Leslie · 1 shared paper, 2024 · strength 0.22
- Paper Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer. DOI 10.14701/ahbps.23-107 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.